• About
• Links
• Contact
• Sitemap
• 

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The scope of this report includes:

Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015

Analysis of the leading therapeutic segments including diabetes and obesity.

Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Global Metabolic Disorders Therapeutics Market: Introduction

• 2.1 Report Guidance

3 Global Metabolic Disorders Therapeutics Market: Market Overview

• 3.1 Introduction
• 3.2 Revenue Forecasts for the Global Metabolic Disorders Therapeutics Market
  • 3.2.1 Sales Value
  • 3.2.2 Sales Volume
  • 3.2.3 Annual Cost of Therapy
  • 3.2.4 Treatment Usage Patterns
  • 3.2.5 Generics’ Share in the Global Metabolic Disorders Therapeutics Market
• 3.3 SWOT Analysis
  • 3.3.1 Strength
  • 3.3.2 Weakness
  • 3.3.3 Opportunity
  • 3.3.4 Threat
• 3.4 Metabolic Disorders Therapeutics Market Drivers
  • 3.4.1 High Unmet Needs in the Obesity Market Create a Huge Market Opportunity for Future Potential Blockbusters
  • 3.4.2 Drastic Raise in Metabolic Disorders Diseased Population in the Developed Countries
  • 3.4.3 Technological Advances in the Diabetic Therapies Market are expected to Enhance Patient Acceptability and Therefore Patient-base
  • 3.4.4 Sedentary Life Styles and Increased Consumption of Fat-rich Products Driving the Growth of Metabolic Disorders Diseased Population
• 3.5 Metabolic Disorders Therapeutics Market Restraints
  • 3.5.1 Severe Side-effects Associated with Metabolic Disorder Drugs are Proving Detrimental to the Growth of the Market
  • 3.5.2 Lack of Proper Reimbursement Coverage in Countries such as Germany and France Restraining the Growth of the Market
  • 3.5.3 Generics Pose Significant Threat to the Global Metabolic Disorders Therapeutics Market

4 Global Metabolic Disorders Therapeutics Market: Therapeutic Landscape

• 4.1 Diabetes Market
  • 4.1.1 Introduction
  • 4.1.2 Unmet Needs
  • 4.1.3 Sales Value
  • 4.1.4 Sales Volume
  • 4.1.5 Annual Cost of Therapy
  • 4.1.6 Treatment Usage Patterns
  • 4.1.7 Geographical Segmentation
  • 4.1.8 Generics’ Share in the Global Diabetes Market
  • 4.1.9 Drivers of Diabetes Market
  • 4.1.10 Restraints of Diabetes Market
• 4.2 Obesity Market
  • 4.2.1 Introduction
  • 4.2.2 Sales Value
  • 4.2.3 Sales Volume
  • 4.2.4 Annual Cost of Therapy
  • 4.2.5 Treatment Usage Patterns
  • 4.2.6 Geographical Segmentation
  • 4.2.7 Generics’ Share in the Global Obesity Market
  • 4.2.8 Drivers of Obesity Market
  • 4.2.9 Restraints of Obesity Market

5 Global Metabolic Disorders Therapeutics Market: Geographical Landscape

• 5.1 Geographical Break-up
• 5.2 The US
  • 5.2.1 Sales Value
  • 5.2.2 Sales Volume
  • 5.2.3 Annual Cost of Therapy
  • 5.2.4 Treatment Usage Patterns
• 5.3 Top Five Countries in Europe
  • 5.3.1 Sales Value
  • 5.3.2 Sales Volume
  • 5.3.3 Annual Cost of Therapy
  • 5.3.4 Treatment Usage Patterns
• 5.4 Japan
  • 5.4.1 Sales Value
  • 5.4.2 Sales Volume
  • 5.4.3 Annual Cost of Therapy
  • 5.4.4 Treatment Usage Patterns

6 Global Metabolic Disorders Therapeutics Market: Pipeline Analysis

• 6.1 Introduction
  • 6.1.1 Research and Development Pipeline - Diabetes
  • 6.1.2 Research and Development Pipeline - Obesity
• 6.2 R&D Trends
  • 6.2.1 New Promising Treatments for Diabetic Retinopathy
  • 6.2.2 Identifying Biomarkers will Mark an Important Step in Metabolic Disorders R&D
  • 6.2.3 Combination Drugs is an Important Part of Diabetes and Obesity Pipeline
  • 6.2.4 First-in-class Insulin Pills (Oral Delivery) in Development
• 6.3 New Drug Insulin Delivery Systems
  • 6.3.1 Altea Therapeutics Transdermal Passport System
  • 6.3.2 Technosphere/Insulin Mimics Early Post-Prandial Insulin Release
• 6.4 Profiles of Key Late-Stage Drugs in the Diabetes Market
  • 6.4.1 Teplizumab
  • 6.4.2 Oral-Lyn
  • 6.4.3 Liraglutide for Diabetes
• 6.5 Profiles of Key Late-Stage Drugs in the Obesity Market
  • 6.5.1 Lorcaserin
  • 6.5.2 Contrave
  • 6.5.3 Liraglutide for Obesity

7 Global Metabolic Disorders Therapeutics Market: Competitive Landscape

• 7.1 Diabetes Market Overview
• 7.2 Market Share Analysis: Diabetes Therapeutics
• 7.3 Obesity Market Overview
• 7.4 Market Share Analysis: Obesity Therapeutics
• 7.5 Competitive Profiling
  • 7.5.1 Diabetes Therapeutics Market
  • 7.5.2 Obesity Therapeutics Market
  • 7.5.3 Human Insulin Products and Oral Antidiabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth
  • 7.5.4 Novo Nordisk
  • 7.5.5 Sanofi-aventis
  • 7.5.6 Takeda
  • 7.5.7 Eli Lilly
  • 7.5.8 GlaxoSmithKline (GSK)
  • 7.5.9 Merck & Co Inc
  • 7.5.10 Amylin Pharmaceuticals
  • 7.5.11 Roche
  • 7.5.12 Abbott

8 Global Metabolic Disorders Therapeutics Market: Strategic Consolidations

• 8.1 Overview
  • 8.1.1 Ligand Pharmaceuticals Acquired Metabasis Therapeutics in October 2009
  • 8.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 2009
  • 8.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009
  • 8.1.4 Pfizer Acquired Wyeth in January 2009
  • 8.1.5 Wyeth Acquired Thiakis Ltd. in December 2008
  • 8.1.6 Bellus Health Inc. Acquired Innodia Inc in July 2008
  • 8.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 2008
  • 8.1.8 Point Therapeutics and Dara Biosciences Merged in February 2008
  • 8.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 2008
• 8.2 R&D Licensing Agreements
  • 8.2.1 Deals by Indication
  • 8.2.2 Deals by Phase
  • 8.2.3 Deals by Geography
  • 8.2.4 Deals by Licensing Type
  • 8.2.5 Deals by Value ($)
  • 8.2.6 Preclinical
  • 8.2.7 Phase I
  • 8.2.8 Phase II
  • 8.2.9 Phase III
  • 8.2.10 Approved

9 Global Metabolic Disorders therapeutics Market: Appendix

• 9.1 Market Definitions
• 9.2 Abbreviations
• 9.3 Research Methodology
  • 9.3.1 Coverage
  • 9.3.2 Secondary Research
  • 9.3.3 Primary Research
  • 9.3.4 Forecasts
  • 9.3.5 Expert Panel Validation
• 9.4 Contact Us
• 9.5 Disclaimer
• 9.6 Sources

1.1 List of Tables

• Table 1: Metabolic Disorders Therapeutics Market, Global, Obesity Classification by Body Mass Index (BMI), 2009
• Table 2: Metabolic Disorders Therapeutics Market, Global, Sales Value ($ bn), 2000-2008
• Table 3: Metabolic Disorders Therapeutics Market, Global, Sales Value ($ bn), 2008-2015
• Table 4: Metabolic Disorders Therapeutics Market, Global, Sales Volume (billion), 2000-2008
• Table 5: Metabolic Disorders Therapeutics Market, Global, Sales Volume (billion), 2008-2015
• Table 6: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2000-2008
• Table 7: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2008-2015
• Table 8: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns, 2000-2008
• Table 9: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns, 2008-2015
• Table 10: Metabolic Disorders Therapeutics Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2008
• Table 11: Metabolic Disorders Therapeutics Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2008-2015
• Table 12: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Value ($ bn), 2000-2008
• Table 13: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Value ($ bn), 2008-2015
• Table 14: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Volume (billion), 2000-2008
• Table 15: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Volume (billion), 2008-2015
• Table 16: Metabolic Disorders Therapeutics Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2008
• Table 17: Metabolic Disorders Therapeutics Market, Global, Diabetes Annual Cost of Therapy ($), 2008-2015
• Table 18: Metabolic Disorders Therapeutics Market, Global, Diabetes Treatment Usage Patterns, 2000-2008
• Table 19: Metabolic Disorders Therapeutics Market, Global, Diabetes Treatment Usage Patterns, 2008-2015
• Table 20: Metabolic Disorders Therapeutics Market, Global, Diabetes Market Geographical Segmentation, 2000-2008
• Table 21: Metabolic Disorders Therapeutics Market, Global, Diabetes Market Geographical Segmentation, 2008-2015
• Table 22: Metabolic Disorders Therapeutics Market, Global, Diabetes Branded Vs Generics, 2000-2008
• Table 23: Metabolic Disorders Therapeutics Market, Global, Diabetes Branded Vs Generics, 2008-2015
• Table 24: Metabolic Disorders Therapeutics Market, Global, Sales Value ($ bn), 2000-2008
• Table 25: Metabolic Disorders Therapeutics Market, Global, Obesity Sales Value ($ bn), 2009-2015
• Table 26: Metabolic Disorders Therapeutics Market, Global, Obesity Market Sales Volume (billion), 2000-2008
• Table 27: Metabolic Disorders Therapeutics Market, Global, Obesity Market Sales Volume (billion), 2008-2015
• Table 28: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Obesity Treatment, 2000-2008
• Table 29: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Obesity Treatment, 2008-2015
• Table 30: Metabolic Disorders Therapeutics Market, Global, Obesity Treatment Usage Patterns, 2000-2008
• Table 31: Metabolic Disorders Therapeutics Market, Global, Obesity Treatment Usage Patterns, 2008-2015
• Table 32: Metabolic Disorders Therapeutics Market, Global, Obesity Market Geographical Segmentation, 2000-2008
• Table 33: Metabolic Disorders Therapeutics Market, Global, Obesity Market Geographical Segmentation, 2008-2015
• Table 34: Metabolic Disorders Therapeutics Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2008
• Table 35: Metabolic Disorders Therapeutics Market, Global, Obesity Market, Generics Vs Branded Drugs, 2008-2015
• Table 36: Metabolic Disorders Therapeutics Market, Global, Sales Value by Geography ($ bn), 2000-2008
• Table 37: Metabolic Disorders Therapeutics Market, Global, Sales Value by Geography ($ bn), 2008-2015
• Table 38: Metabolic Disorders Therapeutics Market, US, Sales Value ($ bn), 2000-2008
• Table 39: Metabolic Disorders Therapeutics Market, US, Sales Value ($ bn), 2008-2015
• Table 40: Metabolic Disorders Therapeutics Market, US, Sales Volume (billion), 2000-2008
• Table 41: Metabolic Disorders Therapeutics Market, US, Sales Volume (billion), 2008-2015
• Table 42: Metabolic Disorders Therapeutics Market, US, Annual Cost of Therapy ($), 2000-2008
• Table 43: Metabolic Disorders Therapeutics Market, US, Annual Cost of Therapy ($), 2008-2015
• Table 44: Metabolic Disorders Therapeutics Market, US, Treatment Usage Patterns, 2000-2008
• Table 45: Metabolic Disorders Therapeutics Market, US, Treatment Usage Patterns, 2008-2015
• Table 46: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2008
• Table 47: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Value ($ bn), 2008-2015
• Table 48: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Volume (billion), 2000-2008
• Table 49: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Volume (billion), 2008-2015
• Table 50: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2008
• Table 51: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2008-2015
• Table 52: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2008
• Table 53: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2008-2015
• Table 54: Metabolic Disorders Therapeutics Market, Japan, Sales Value ($ bn), 2000-2008
• Table 55: Metabolic Disorders Therapeutics Market, Japan, Sales Value ($ bn), 2008-2015
• Table 56: Metabolic Disorders Therapeutics Market, Japan, Sales Value ($ bn), 2000-2008
• Table 57: Metabolic Disorders Therapeutics Market, Japan, Sales Value ($ bn), 2008-2015
• Table 58: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2000-2008
• Table 59: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2008-2015
• Table 60: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Patterns, 2000-2008
• Table 61: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Patterns, 2008-2015
• Table 62: Metabolic Disorders Therapeutics Market, Global, Mechanism of Action of Diabetes Drugs
• Table 63: Metabolic Disorders Therapeutics Market, Global, Mechanism of Action of Obesity Drugs
• Table 64: Metabolic Disorders Therapeutics Market, Global, Competitive Landscape for Diabetes Market, 2008
• Table 65: Metabolic Disorders Therapeutics Market, Global, Competitive Landscape for Obesity Market, 2008
• Table 66: Metabolic Disorders Therapeutics Market, Novo Nordisk, Pipeline Products, December 2009
• Table 67: Metabolic Disorders Therapeutics Market, Sanofi-aventis, Pipeline Products, December 2009
• Table 68: Metabolic Disorders Therapeutics Market, Takeda, Pipeline Products, 2009
• Table 69: Metabolic Disorders Therapeutics Market, Eli Lilly, Pipeline Products, December 2009
• Table 70: Metabolic Disorders Therapeutics Market, GSK, Pipeline Products, December 2009
• Table 71: Metabolic Disorders Therapeutics Market, Merck, Pipeline Products, December 2009
• Table 72: Metabolic Disorders Therapeutics Market, Amylin, Pipeline Products, December 2009
• Table 73: Metabolic Disorders Therapeutics Market, Roche, Pipeline Products, December 2009
• Table 74: Metabolic Disorders Therapeutics Market, Global, Major M&A Deals, 2008-2009
• Table 75: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009
• Table 76: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009
• Table 77: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009
• Table 78: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009
• Table 79: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-2009
• Table 80: Metabolic Disorders Therapeutics Market, Global, Currency Conversion Rate, 2006-2008

1.2 List of Figures

• Figure 1: Metabolic Disorders Therapeutics Market, Global, Sales Value ($ bn), 2000-2015
• Figure 2: Metabolic Disorders Therapeutics Market, Global, Sales Volume (billion), 2000-2015
• Figure 3: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2000-2015
• Figure 4: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns, 2000-2015
• Figure 5: Metabolic Disorders Therapeutics Market, Global, Diseased Population (million), 2000-2015
• Figure 6: Metabolic Disorders Therapeutics Market, Global, Treatment Seeking Population (million), 2000-2015
• Figure 7: Metabolic Disorders Therapeutics Market, Global, Diagnosed Population (million), 2000-2015
• Figure 8: Metabolic Disorders Therapeutics Market, Global, Prescription Population (million), 2000-2015
• Figure 9: Metabolic Disorders Therapeutics Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2015
• Figure 10: Metabolic Disorders Therapeutics Market, Global, SWOT Analysis, 2008
• Figure 11: Metabolic Disorders Therapeutics Market, Global, Drivers and Restraints, 2008
• Figure 12: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Value ($ bn), 2000-2015
• Figure 13: Metabolic Disorders Therapeutics Market, Global, Diabetes Sales Volume (billion), 2000-2015
• Figure 14: Metabolic Disorders Therapeutics Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2015
• Figure 15: Metabolic Disorders Therapeutics Market, Global, Diabetes Treatment Usage Patterns, 2000-2015
• Figure 16: Metabolic Disorders Therapeutics Market, Global, Diabetes Diseased Population, 2000-2015
• Figure 17: Metabolic Disorders Therapeutics Market, Global, Diabetes Treatment Seeking Population, 2000-2015
• Figure 18: Metabolic Disorders Therapeutics Market, Global, Diabetes Diagnosed Population, 2000-2015
• Figure 19: Metabolic Disorders Therapeutics Market, Global, Diabetes Prescription Population, 2000-2015
• Figure 20: Metabolic Disorders Therapeutics Market, Global, Diabetes Market Segmentation by Geography, 2008 and 2015
• Figure 21: Metabolic Disorders Therapeutics Market, Global, Diabetes Market in the Top Five Countries in Europe, 2008 and 2015
• Figure 22: Metabolic Disorders Therapeutics Market, Global, Diabetes Market Geographical Segmentation, 2000-2015
• Figure 23: Metabolic Disorders Therapeutics Market, Global, Diabetes Market, Geography Benchmarking, 2008
• Figure 24: Metabolic Disorders Therapeutics Market, Global, Diabetes Branded Vs Generics, 2000-2015
• Figure 25: Metabolic Disorders Therapeutics Market, Global, Diabetes Market, Generics Share, 2008 and 2015
• Figure 26: Metabolic Disorders Therapeutics Market, Global, Diabetes Market Drivers and Restraints, 2008
• Figure 27: Metabolic Disorders Therapeutics Market, Global, Obesity Sales Value ($ bn), 2000-2015
• Figure 28: Metabolic Disorders Therapeutics Market, Global, Obesity Market Sales Volume (billion), 2000-2015
• Figure 29: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Obesity Treatment, 2000-2015
• Figure 30: Metabolic Disorders Therapeutics Market, Global, Obesity Treatment Usage Patterns, 2000-2015
• Figure 31: Metabolic Disorders Therapeutics Market, Global, Obesity Diseased Population, 2000-2015
• Figure 32: Metabolic Disorders Therapeutics Market, Global, Obesity Treatment Seeking Population, 2000-2015
• Figure 33: Metabolic Disorders Therapeutics Market, Global, Obesity Diagnosed Population, 2000-2015
• Figure 34: Metabolic Disorders Therapeutics Market, Global, Obesity Prescription Population, 2000-2015
• Figure 35: Metabolic Disorders Therapeutics Market, Global, Obesity Market Geographical Segmentation, 2000-2015
• Figure 36: Metabolic Disorders Therapeutics Market, Global, Obesity Market Distribution by Geography, 2008 and 2015
• Figure 37: Metabolic Disorders Therapeutics Market, Global, Obesity Market, Geography Benchmarking, 2008 and 2015
• Figure 38: Metabolic Disorders Therapeutics Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2015
• Figure 39: Metabolic Disorders Therapeutics Market, Global, Obesity Market, Generics Vs Branded Drugs Market Share, 2008 and 2015
• Figure 40: Metabolic Disorders Therapeutics Market, Global, Obesity Market Drivers and Restraints, 2008
• Figure 41: Metabolic Disorders Therapeutics Market, Global, Market Share by Geography, 2008 and 2015
• Figure 42: Metabolic Disorders Therapeutics Market, Global, Sales Value by Geography ($ bn), 2000-2015
• Figure 43: Metabolic Disorders Therapeutics Market, Global, Geography Benchmarking, 2008 and 2015
• Figure 44: Metabolic Disorders Therapeutics Market, US, Sales Value ($ bn), 2000-2015
• Figure 45: Metabolic Disorders Therapeutics Market, US, Sales Volume (billion), 2000-2015
• Figure 46: Metabolic Disorders Therapeutics Market, US, Annual Cost of Therapy ($), 2000-2015
• Figure 47: Metabolic Disorders Therapeutics Market, US, Treatment Usage Patterns, 2000-2015
• Figure 48: Metabolic Disorders Therapeutics Market, US, Diseased Population, 2000-2015
• Figure 49: Metabolic Disorders Therapeutics Market, US, Treatment Seeking Population, 2000-2015
• Figure 50: Metabolic Disorders Therapeutics Market, US, Diagnosed Population, 2000-2015
• Figure 51: Metabolic Disorders Therapeutics Market, US, Prescription Population, 2000-2015
• Figure 52: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2015
• Figure 53: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Sales Volume (billion), 2000-2015
• Figure 54: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2015
• Figure 55: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2015
• Figure 56: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2000-2015
• Figure 57: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2000-2015
• Figure 58: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 2000-2015
• Figure 59: Metabolic Disorders Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2000-2015
• Figure 60: Metabolic Disorders Therapeutics Market, Japan, Sales Value ($ bn), 2000-2015
• Figure 61: Metabolic Disorders Therapeutics Market, Japan, Sales Volume ($ bn), 2000-2015
• Figure 62: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2000-2015
• Figure 63: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Patterns, 2000-2015
• Figure 64: Metabolic Disorders Therapeutics Market, Japan, Diseased Population, 2000-2015
• Figure 65: Metabolic Disorders Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015
• Figure 66: Metabolic Disorders Therapeutics Market, Japan, Diagnosed Population, 2000-2015
• Figure 67: Metabolic Disorders Therapeutics Market, Japan, Prescription Population, 2000-2015
• Figure 68: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Indication, December 2009
• Figure 69: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase, December 2009
• Figure 70: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Diabetes Market, December 2009
• Figure 71: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Type 1 Diabetes Market, December 2009
• Figure 72: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Type 2 Diabetes Market, December 2009
• Figure 73: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Obesity Market, December 2009
• Figure 74: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Company in Obesity Market, December 2009
• Figure 75: Metabolic Disorders Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
• Figure 76: Metabolic Disorders Therapeutics Market, Global, Revenue of Top Six Players in Diabetes Market, 2006-2008
• Figure 77: Metabolic Disorders Therapeutics Market, Global, Competitive Analysis of Top Six Players in Diabetes Market, 2006-2008
• Figure 78: Metabolic Disorders Therapeutics Market, Global, Market Share of Top Manufacturers in Diabetes Market, 2008
• Figure 79: Metabolic Disorders Therapeutics Market, Global, Revenue of Top Three Players in Obesity Market, 2006-2008
• Figure 80: Metabolic Disorders Therapeutics Market, Global, Competitive Analysis of Top Three Players in Obesity Market, 2006-2008
• Figure 81: Obesity Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
• Figure 82: Metabolic Disorders Therapeutics Market, Global, Sales of Leading Drugs, 2006-2008
• Figure 83: Metabolic Disorders Therapeutics Market, Novo Nordisk, Revenue Segment, n = $9bn, 2008
• Figure 84: Metabolic Disorders Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product, n = $6.6bn, 2008
• Figure 85: Metabolic Disorders Therapeutics Market, Sanofi-aventis, Diabetes Revenue Segment, n = $40.6bn, 9M FY2009
• Figure 86: Metabolic Disorders Therapeutics Market, Sanofi-aventis, Diabetes Revenue by Product, n = $4.3bn, 2008
• Figure 87: Metabolic Disorders Therapeutics Market, Takeda, Revenue Segment, n = $15bn, 2008
• Figure 88: Metabolic Disorders Therapeutics Market, Eli Lilly, Revenue Segment, n = $20.4bn, 2008
• Figure 89: Metabolic Disorders Therapeutics Market, Eli Lilly, Diabetes Revenue by Product, n = $3.5bn, 2008
• Figure 90: Metabolic Disorders Therapeutics Market, GSK, Revenue Segment, n = $45.2bn, 2008
• Figure 91: Metabolic Disorders Therapeutics Market, GSK, Diabetes Revenue by Product, n = $1.4bn, 2008
• Figure 92: Metabolic Disorders Therapeutics Market, Merck, Diabetes Revenue as Percentage of Total Revenue, n = $23.8bn, 2008
• Figure 93: Metabolic Disorders Therapeutics Market, Amylin, Diabetes Revenue as Percentage of Total Revenue, n = $840m, 2008
• Figure 94: Metabolic Disorders Therapeutics Market, Amylin, Diabetes Revenue by Product, n = $765m, 2008
• Figure 95: Metabolic Disorders Therapeutics Market, Roche, Revenue Segment, n = $42.2bn, 2008
• Figure 96: Metabolic Disorders Therapeutics Market, Abbott, Revenue Segment, n = $29.5bn, 2008
• Figure 97: Metabolic Disorders Therapeutics Market, Global, M&A Deals by Indication, 2008-2009
• Figure 98: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Indication, 2008-2009
• Figure 99: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-2009
• Figure 100: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-2009
• Figure 101: Metabolic Disorders Therapeutics Market, Global, Major Agreements By Type, 2008-2009
• Figure 102: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Value, 2008-2009, n=10
• Figure 103: Research Methodology
• Figure 104: Research Market Forecasting Model

Other users found this report page using the following search terms: diabetes obesity Metabolic Disorder metabolic market disorder therapeutics metabolics marketsize uk disease marketvaluemetabolicdiseases diabeticretinopathyworldmarketbillion2020 metabolicdisordermarket2009billion

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.